Cargando…
Checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475490/ https://www.ncbi.nlm.nih.gov/pubmed/32953835 http://dx.doi.org/10.21037/atm.2020.04.06 |
| _version_ | 1783579517290283008 |
|---|---|
| author | Balzarotti, Monica Santoro, Armando |
| author_facet | Balzarotti, Monica Santoro, Armando |
| author_sort | Balzarotti, Monica |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7475490 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74754902020-09-17 Checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients? Balzarotti, Monica Santoro, Armando Ann Transl Med Editorial Commentary AME Publishing Company 2020-08 /pmc/articles/PMC7475490/ /pubmed/32953835 http://dx.doi.org/10.21037/atm.2020.04.06 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Balzarotti, Monica Santoro, Armando Checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients? |
| title | Checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients? |
| title_full | Checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients? |
| title_fullStr | Checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients? |
| title_full_unstemmed | Checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients? |
| title_short | Checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients? |
| title_sort | checkpoint inhibitors in primary mediastinal b-cell lymphoma: a step forward in refractory/relapsing patients? |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475490/ https://www.ncbi.nlm.nih.gov/pubmed/32953835 http://dx.doi.org/10.21037/atm.2020.04.06 |
| work_keys_str_mv | AT balzarottimonica checkpointinhibitorsinprimarymediastinalbcelllymphomaastepforwardinrefractoryrelapsingpatients AT santoroarmando checkpointinhibitorsinprimarymediastinalbcelllymphomaastepforwardinrefractoryrelapsingpatients |